On or off target: mutations, models, and predictions.

Abstract excerpt

In a series of articles published in February 2010, The New York Times chronicled, from a personal perspective, the rollercoaster experience of those associated with clinical trials of a RAF inhibitor for the treatment of melanoma. In this issue of Science Translational Medicine, Whittaker et al. describe research that reconciles some of the bewildering aspects of the discovery and development of drugs that...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Models, Molecular
• Share to Neoplasms
• Share to Antineoplastic Agents